Extragonadal Embryonal Carcinoma
NCI Definition: An embryonal carcinoma that develops as a primary tumor in an anatomic site other than the testis or ovary. 
Extragonadal embryonal carcinomas most frequently harbor alterations in CDKN1B, RAD52, PIK3C2G, KRAS, and KDM5A .
CDKN1B Amplification, RAD52 Amplification, PIK3C2G Amplification, KRAS Amplification, and KDM5A Amplification are the most common alterations in extragonadal embryonal carcinoma .
There are 5 clinical trials for extragonadal embryonal carcinoma, of which 3 are open and 2 are completed or closed. Of the trials that contain extragonadal embryonal carcinoma as an inclusion criterion, 2 are phase 1 (2 open) and 3 are phase 2 (1 open).
Aldesleukin, cyclophosphamide, and fludarabine are the most common interventions in extragonadal embryonal carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.